| Title |
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
|
|---|---|
| Published in |
Cancer Management and Research, June 2017
|
| DOI | 10.2147/cmar.s136818 |
| Pubmed ID | |
| Authors |
Sarah Chuzi, Fabio Tavora, Marcelo Cruz, Ricardo Costa, Young Kwang Chae, Benedito A Carneiro, Francis J Giles |
| Abstract |
Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies. |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 111 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 16 | 14% |
| Researcher | 15 | 13% |
| Student > Bachelor | 12 | 11% |
| Student > Master | 10 | 9% |
| Student > Doctoral Student | 9 | 8% |
| Other | 21 | 19% |
| Unknown | 29 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 58 | 52% |
| Nursing and Health Professions | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Engineering | 2 | 2% |
| Other | 8 | 7% |
| Unknown | 29 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2019.
All research outputs
#1,631,865
of 22,986,950 outputs
Outputs from Cancer Management and Research
#33
of 2,014 outputs
Outputs of similar age
#34,184
of 316,523 outputs
Outputs of similar age from Cancer Management and Research
#1
of 15 outputs
Altmetric has tracked 22,986,950 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,014 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,523 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.